AngioDynamics has expanded indications across Europe for its NanoKnife System to include soft tissue ablation for tumours in the liver, kidney, prostate and pancreas, including use in patients with intermediate-risk prostate cancer.
This development extends access to the system’s irreversible electroporation (IRE) technology for clinicians addressing tumours that are difficult to resect or close to critical structures.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The solution employs non-thermal IRE ablation to destroy tumour cells while preserving surrounding anatomy such as blood vessels, nerves, and bile ducts. This mechanism of action is well-suited for tumours in anatomically complex locations like the liver and pancreas.
Clinical research demonstrates the procedural feasibility of IRE technology in various solid tumour contexts, including hepatocellular carcinoma, metastatic colorectal cancer, and renal tumours.
Both prospective studies and real-world analyses continue to validate the safety profile and expanding clinical utility of IRE for challenging anatomical disease states.
To facilitate further clinical adoption and evidence development, AngioDynamics will launch the LIVER-IRE Global Registry in partnership with University of Manchester professor Ajith Siriwardena.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe registry will prospectively assess outcomes in patients receiving IRE treatment for liver tumours, enriching real-world data on multi-organ applications of the NanoKnife system.
AngioDynamics senior vice-president and cardiovascular and international general manager Laura Piccinini said: “NanoKnife prostate continues to gain clinical traction, and we remain committed to advancing that indication globally.
“The expansion of additional organ indications in Europe underscores the broader potential of IRE technology and strengthens NanoKnife as a scalable platform for complex tumour ablation. Our goal is to ensure physicians have access to differentiated tools that expand treatment options for patients across multiple disease states.”
In October 2024, AngioDynamics collaborated with University College London Hospital (UCLH) in the UK to initiate a prospective registry study of the NanoKnife system’s long-term effects in the treatment of unifocal intermediate-risk prostate cancer.
